Bard Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bard Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37	Closed	-$2.25K	–	301
2026 Q1	$2.25K	Buy	+37	New	+$2.16K	﹤0.01%	268

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bard Associates's BMY Position: Q2 2026 in Review

Bard Associates sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 37 shares — an estimated $2.25K sold.

Bard Associates first reported a position in BMY in Q1 2026 and held it in 1 quarter. The position peaked at $2.25K in Q1 2026. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Bard Associates reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Bard Associates sold 37 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.25K.
Bard Associates first reported a position in Bristol-Myers Squibb in Q1 2026 and held it in 1 quarter.
Bard Associates's Bristol-Myers Squibb position peaked at $2.25K in Q1 2026.
2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.